Skip to content

Author

A. Henao-Martínez

We have 4 of 227 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Clinical Phenotypes, Immunosuppressive Exposures, and Outcomes in Pulmonary vs Extrapulmonary Cryptococcosis Among Non-HIV, Non-Transplant Adults: A U.S. Claims Analysis

Abstract Introduction Cryptococcosis increasingly affects non-HIV, non-transplant (NHNT) adults, but factors associated with extrapulmonary dissemination remain incompletely defined. We evaluated associations between comorbidities, immunosuppressive therapy, and cryptococcal disease phenotype. Method NHNT adults with c...

Ameera Jamshad, Bayard A. Taylor, Guo-Zheng Yang et al. · 0 citations
Open access Oct 2026

Factors associated with 90-day mortality in adults with cryptococcal meningoencephalitis across HIV, solid organ transplant, and non-HIV, non-transplant populations.

PURPOSE Predictors of mortality in cryptococcal meningoencephalitis (CM) across HIV, solid organ transplant (SOT), and non-HIV, non-transplant (NHNT) populations remain incompletely defined. We compared clinical characteristics and 90-day mortality across host groups and evaluated factors associated with mortality. M...

Bayard A. Taylor, Ameera Jamshad, A. Henao-Martínez et al. · 0 citations
Oct 2026

Clinical Characteristics and Predictors of Hospitalization of Leprosy in the United States: A Multicenter Network Analysis.

Leprosy, also known as Hansen's disease, is a chronic infection caused by Mycobacterium leprae or Mycobacterium lepromatosis. Although global prevalence has decreased, the number of cases each year has plateaued at ∼200,000. In the United States, sporadic cases continue to occur, primarily in the southern states. A ret...

Samantha R. Kaplan, Oscar Bernat, Christian Olivo-Freites et al. · 0 citations
Review Jul 2026

Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections

A narrative review, including the pharmacological characteristics of dalbavancin (DAL) and oritavancin (ORI), the only currently available laLGPs, as well as their approved and “off-label” use reported in the literature to date.

Madison E. Salam, D. Chastain, Douglas N. Fish et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.